PBYI - Puma Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.22
-0.25 (-0.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close25.47
Open25.48
Bid25.22 x 3000
Ask26.00 x 900
Day's Range24.66 - 25.76
52 Week Range17.60 - 95.05
Volume703,161
Avg. Volume1,482,446
Market Cap961.765M
Beta (3Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit5 days ago

    See what the IHS Markit Score report has to say about Puma Biotechnology Inc.

    # Puma Biotechnology Inc ### NASDAQ/NGS:PBYI View full report here! ## Summary * Bearish sentiment is moderate ## Bearish sentiment Short interest | Negative Short interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.19 billion over the last one-month into ETFs that hold PBYI are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why
    Zacks10 days ago

    Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

    Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

  • Athenex Completes Enrollment Target for Breast Cancer Study
    Zacks11 days ago

    Athenex Completes Enrollment Target for Breast Cancer Study

    Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Puma Biotechnology Inc.

    # Puma Biotechnology Inc ### NASDAQ/NGS:PBYI View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Negative Short interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding PBYI is favorable, with net inflows of $5.45 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Markitlast month

    See what the IHS Markit Score report has to say about Puma Biotechnology Inc.

    # Puma Biotechnology Inc ### NASDAQ/NGS:PBYI View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Negative Short interest is moderately high for PBYI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding PBYI are favorable, with net inflows of $1.87 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzingalast month

    A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial

    Puma Biotechnology Inc (NASDAQ: PBYI ) released positive top-line results for its lead drug candidate PB272, or Nerlynx, which is being evaluated for treating HER2+ metastatic breast cancer patients who ...

  • Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
    Zackslast month

    Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer

    Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.

  • Benzingalast month

    The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...

  • MarketWatchlast month

    Puma Bio stock rises more than 9% on drug study

    Shares of Puma Biotechnology Inc. rose more than 9% in the extended session Monday after the company said it has reached an agreement with the Food and Drug Administration to devise further trials for one of its drug candidates designed to treat some types of metastatic breast cancer. The company said top-line results of one of the drug's trial stages showed some improvement in survival rates. "We look forward to working with the regulatory authorities in the hope of bringing another potential treatment option to patients with HER2-positive metastatic breast cancer as soon as possible," Chief Executive Alan H. Auerbach said in a statement. Puma shares ended the regular trading day down 5%.

  • Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged
    Insider Monkeylast month

    Puma Biotechnology Inc (PBYI): Hedge Fund Sentiment Unchanged

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]

  • 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
    Motley Foollast month

    3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019

    A new year and reasons to remain hopeful for these three biotechs are around the corner.

  • Here's Why Puma Biotechnology Tanked 37.3% in November
    Motley Fool2 months ago

    Here's Why Puma Biotechnology Tanked 37.3% in November

    Third-quarter earnings suggest Nerlynx sales aren't going to meet expectations.

  • Why Clovis Oncology Stock Rose 48% in November
    Market Realist2 months ago

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30. Clovis Oncology’s stock price grew from $11.63 at the close of business on October 31 to $17.21 at the close of the market on November 30, which reflects ~48% growth in November.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PBYI earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Puma Biotechnology Inc Earnings Call

  • Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
    Market Realist2 months ago

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.

  • NERLYNX: Market Expansion and Label Expansion
    Market Realist2 months ago

    NERLYNX: Market Expansion and Label Expansion

    In a press release on July 31, Puma Biotechnology (PBYI) announced that Health Canada would review the company’s New Drug Submission for NERLYNX in the extended adjuvant setting for early-stage HER2-positive breast cancer after Herceptin-based adjuvant therapy.

  • NERLYNX: Major Growth Driver for PBYI
    Market Realist2 months ago

    NERLYNX: Major Growth Driver for PBYI

    Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter, which is higher than its revenues of $50.8 million reported in the second quarter. According to the company’s third-quarter earnings conference call, Puma Biotechnology has attributed the growth to an increase in the number of patients being prescribed NERLYNX and patients choosing to stay on the therapy.

  • Puma Biotechnology: Revenue Projections for 2018
    Market Realist2 months ago

    Puma Biotechnology: Revenue Projections for 2018

    According to Puma Biotechnology’s (PBYI) third-quarter earnings conference call, the company expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018. The company has provided a conservative guidance range—assuming that there might be lower patient starts in November and December due to the holidays.

  • Puma Biotechnology: Analysts’ Recommendations
    Market Realist2 months ago

    Puma Biotechnology: Analysts’ Recommendations

    On November 1, Puma Biotechnology (PBYI) closed at $20.07, which was 48.01% lower than its previous closing price. The stock has fallen  78.34% from $92.65 on January 2 to $20.07 on November 2. Puma Biotechnology stock rose 13.90% compared to its previous closing price and closed at $22.86 on November 5.

  • Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
    Zacks3 months ago

    Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down

    Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.

  • Here's Why Puma Biotechnology Inc. Is Getting Hammered Today
    Motley Fool3 months ago

    Here's Why Puma Biotechnology Inc. Is Getting Hammered Today

    Sales of the company's lead drug just aren't living up to expectations.

  • MarketWatch3 months ago

    Puma Biotechnology's stock plunges to pace premarket losers after key drug Nerlynx disappoints

    Shares of Puma Biotechnology Inc. plummeted 38% toward a 2 1/2-year low, to pace all premarket decliners, after the company reported third-quarter earnings and revenue that beat expectations, but reported disappointing results of its key product, the breast cancer treatment Nerlynx. That prompted J.P. Morgan to swing to bearish from bullish and slash its stock price target. Total revenue rose to $62.6 million from $6.1 million a year ago, topping the FactSet consensus of $57.9 million, but Nerlynx sales of $52.6 million was below expectations of $58.1 million. The company said late Thursday on the post-earnings conference call with analysts that the percentage of patients who discontinued the use of Nerlynx because of adverse events increased to about 18%. J.P. Morgan's Cory Kasimov downgraded Puma to underweight from overweight and cut his price target to $23 from $83. "There simply doesn't appear to be enough new patient starts to offset the discontinuations and patients rolling off [Nerlynx] therapy after 12 months," Kasimov wrote in a note to clients. the stock had already tumbled 61% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 1.2% and the S&P 500 had tacked on 2.5%.

  • Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates

    Puma Biotech (PBYI) delivered earnings and revenue surprises of 65.42% and 13.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Puma Biotech: 3Q Earnings Snapshot

    On a per-share basis, the Los Angeles-based company said it had a loss of 37 cents. The biopharmaceutical company posted revenue of $62.6 million in the period. Puma Biotech shares have dropped 61 percent ...

  • Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today
    Motley Fool3 months ago

    Why Puma Biotechnology, Inc. Stock Is Getting Crushed Today

    Puma's third-quarter numbers fail to impress Wall Street.